Form 4: Sana Biotechnology Director Joshua H. Bilenker Reports Stock Option Grant

Director Joshua H. Bilenker reports the acquisition of stock options in Sana Biotechnology, Inc.

Summary

• Joshua H. Bilenker, a director of Sana Biotechnology, Inc., reported the acquisition of stock options on June 6, 2024.
• The stock option grants him the right to buy 54,278 shares of common stock at an exercise price of $7.36.
• The options vest on the earlier of June 6, 2025, or immediately prior to the 2025 annual meeting of stockholders, contingent upon continuous service to Sana Biotechnology, Inc.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock option grants, and does not contain information that would significantly impact sentiment positively or negatively.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded biotechnology companies.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their compensation strategy to incentivize performance and align management's interests with shareholder value.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, incentivizing them to work towards increasing shareholder value.

Key Dates